The combination treatment caused a significant delay in tumor growth relative to Olaparib or AZD6738 alone in the HCT116 IDH1-mutant flank model without any significant change in body weight (Figure 6B, Supplementary Figure S7A and B). Here, IDH1 is linked to neoplasm.